Finch Therapeutics Group, Inc., (FNCH): Price and Financial Metrics
GET POWR RATINGS... FREE!
FNCH Stock Summary
- FNCH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
- With a year-over-year growth in debt of 811.69%, FINCH THERAPEUTICS GROUP INC's debt growth rate surpasses 97.54% of about US stocks.
- As for revenue growth, note that FNCH's revenue has grown -91.05% over the past 12 months; that beats the revenue growth of just 1.28% of US companies in our set.
- Stocks that are quantitatively similar to FNCH, based on their financial statements, market capitalization, and price volatility, are ZLAB, SRDX, ALBO, ONTX, and HCWB.
- FNCH's SEC filings can be seen here. And to visit FINCH THERAPEUTICS GROUP INC's official web site, go to www.finchtherapeutics.com.
FNCH Valuation Summary
- In comparison to the median Healthcare stock, FNCH's price/sales ratio is 607.32% higher, now standing at 14.5.
- FNCH's EV/EBIT ratio has moved up 22.5 over the prior 22 months.
Below are key valuation metrics over time for FNCH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FNCH | 2023-01-20 | 14.5 | 0.2 | -0.2 | 0.1 |
| FNCH | 2023-01-19 | 15.0 | 0.2 | -0.2 | 0.1 |
| FNCH | 2023-01-18 | 14.5 | 0.2 | -0.2 | 0.1 |
| FNCH | 2023-01-17 | 15.9 | 0.2 | -0.2 | 0.1 |
| FNCH | 2023-01-13 | 16.2 | 0.2 | -0.3 | 0.1 |
| FNCH | 2023-01-12 | 16.2 | 0.2 | -0.3 | 0.1 |
FNCH Price Target
For more insight on analysts targets of FNCH, see our FNCH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $29.67 | Average Broker Recommendation | 1.17 (Strong Buy) |
FNCH Stock Price Chart Interactive Chart >
FNCH Price/Volume Stats
| Current price | $0.52 | 52-week high | $9.28 |
| Prev. close | $0.48 | 52-week low | $0.30 |
| Day low | $0.47 | Volume | 381,500 |
| Day high | $0.54 | Avg. volume | 177,089 |
| 50-day MA | $0.68 | Dividend yield | N/A |
| 200-day MA | $1.86 | Market Cap | 24.91M |
Finch Therapeutics Group, Inc., (FNCH) Company Bio
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Latest FNCH News From Around the Web
Below are the latest news stories about FINCH THERAPEUTICS GROUP INC that investors may wish to consider to help them evaluate FNCH as an investment opportunity.
Finch Therapeutics Group (FNCH) Investor Presentation - Slideshow (NASDAQ:FNCH)The following slide deck was published by Finch Therapeutics Group, Inc. |
Analysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kezar Life Sciences (KZR – Research Report), RVL Pharmaceuticals (RVLP – Research Report) and Finch Therapeutics Group (FNCH – Research Report) with bullish sentiments. Kezar Life Sciences (KZR) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences, with a price target of $21.00. The company's shares closed last Thursday at $7.23. According to TipRanks. |
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsSOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022. |
Finch Therapeutics GAAP EPS of -$0.85 misses by $0.45Finch Therapeutics press release (FNCH): Q3 GAAP EPS of -$0.85 misses by $0.45.Finch’s cash and cash equivalents as of September 30, 2022 were $85.3 million, compared to $133.5… |
Finch Therapeutics Group, Inc. (FNCH) Reports Q3 Loss, Misses Revenue EstimatesFinch Therapeutics Group, Inc. (FNCH) delivered earnings and revenue surprises of -12.50% and 90.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
FNCH Price Returns
| 1-mo | 38.67% |
| 3-mo | -61.19% |
| 6-mo | -73.33% |
| 1-year | -93.15% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 8.33% |
| 2022 | -95.19% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...